Model for End-Stage Liver Disease (MELD) exception for ascites

Liver Transplantation

Volumn 12, Issue 12 SUPPL. 3, 2006, Pages

  Biggins, Scott W ^a   Colquhoun, Steven ^b   Gish, Robert G ^c   Runyon, Bruce A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; SODIUM; SPIRONOLACTONE;

ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLEEDING DISORDER; BRAIN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; GRAFT SURVIVAL; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; LIVER DISEASE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; SURGICAL MORTALITY; SURGICAL RISK;

ASCITES; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; SODIUM; TISSUE AND ORGAN PROCUREMENT;

EID: 33845491492     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20963     Document Type: Article

References (22)

1. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 2005;5:2244-2247.
2. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-266.
3. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
4. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236.
5. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858.
6. Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
7. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
8. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810.
9. Heuman DM, Mihas A. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 2003; 125:992-993.
10. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
11. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-153.
12. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999; 107:262-267.
13. Saab S, Nieto JM, Ly D, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004:CD004889.
14. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634-641.
15. Ripoll C, Banares R, Rincon D, Catalina MV, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology 2005;42:793-801.
16. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol 2001;21: 157-172.
17. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-328.
18. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989; 15:261-266.
19. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J Med 1965;39:184-198.
20. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41: 32-39.
21. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336-343.
22. Biggins S, Kim W, Terrault N, Saab S, Balan V, Schiano T, Benson J, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130:1652-1660.